238 related articles for article (PubMed ID: 23292524)
1. Full-field electroretinogram findings in children in the atropine treatment for myopia (ATOM2) study.
Chia A; Li W; Tan D; Luu CD
Doc Ophthalmol; 2013 Jun; 126(3):177-86. PubMed ID: 23292524
[TBL] [Abstract][Full Text] [Related]
2. Multifocal electroretinogram in children on atropine treatment for myopia.
Luu CD; Lau AM; Koh AH; Tan D
Br J Ophthalmol; 2005 Feb; 89(2):151-3. PubMed ID: 15665343
[TBL] [Abstract][Full Text] [Related]
3. Effect of low-dose atropine on myopia progression, pupil diameter and accommodative amplitude: low-dose atropine and myopia progression.
Fu A; Stapleton F; Wei L; Wang W; Zhao B; Watt K; Ji N; Lyu Y
Br J Ophthalmol; 2020 Nov; 104(11):1535-1541. PubMed ID: 32086237
[TBL] [Abstract][Full Text] [Related]
4. The acute effect of atropine eye drops on the human full-field electroretinogram.
Khanal S; Rathod SN; Phillips JR
Doc Ophthalmol; 2021 Jun; 142(3):315-328. PubMed ID: 33231734
[TBL] [Abstract][Full Text] [Related]
5. Impact of Various Concentrations of Low-Dose Atropine on Pupillary Diameter and Accommodative Amplitude in Children with Myopia.
Tran HDM; Ha TTX; Tran YH; Coroneo M; Tran TD; Truong TU; Sankaridurg P
J Ocul Pharmacol Ther; 2024 May; 40(4):232-239. PubMed ID: 38621178
[No Abstract] [Full Text] [Related]
6. Little effect of 0.01% atropine eye drops as used in myopia prevention on the pattern electroretinogram.
Anders LM; Heinrich SP; Lagrèze WA; Joachimsen L
Doc Ophthalmol; 2019 Apr; 138(2):85-95. PubMed ID: 30680489
[TBL] [Abstract][Full Text] [Related]
7. Additive effect of atropine eye drops and short-term retinal defocus on choroidal thickness in children with myopia.
Chiang ST; Turnbull PRK; Phillips JR
Sci Rep; 2020 Oct; 10(1):18310. PubMed ID: 33110130
[TBL] [Abstract][Full Text] [Related]
8. Paediatric norms for photopic electroretinogram testing based on a large cohort of Chinese preschool children.
Chan SS; Choi KY; Chan HH
BMJ Open Ophthalmol; 2024 Feb; 9(1):. PubMed ID: 38388004
[TBL] [Abstract][Full Text] [Related]
9. Atropine for the treatment of childhood myopia: effect on myopia progression after cessation of atropine.
Tong L; Huang XL; Koh AL; Zhang X; Tan DT; Chua WH
Ophthalmology; 2009 Mar; 116(3):572-9. PubMed ID: 19167081
[TBL] [Abstract][Full Text] [Related]
10. Analysis of Changes in Refraction and Biometry of Atropine- and Placebo-Treated Eyes.
Kumaran A; Htoon HM; Tan D; Chia A
Invest Ophthalmol Vis Sci; 2015 Aug; 56(9):5650-5. PubMed ID: 26313301
[TBL] [Abstract][Full Text] [Related]
11. Effect of axial length on full-field and multifocal electroretinograms.
Sachidanandam R; Ravi P; Sen P
Clin Exp Optom; 2017 Nov; 100(6):668-675. PubMed ID: 28266057
[TBL] [Abstract][Full Text] [Related]
12. Risk factors for progressive myopia in the atropine therapy for myopia study.
Loh KL; Lu Q; Tan D; Chia A
Am J Ophthalmol; 2015 May; 159(5):945-9. PubMed ID: 25640408
[TBL] [Abstract][Full Text] [Related]
13. Low-Concentration Atropine for Myopia Progression (LAMP) Study: A Randomized, Double-Blinded, Placebo-Controlled Trial of 0.05%, 0.025%, and 0.01% Atropine Eye Drops in Myopia Control.
Yam JC; Jiang Y; Tang SM; Law AKP; Chan JJ; Wong E; Ko ST; Young AL; Tham CC; Chen LJ; Pang CP
Ophthalmology; 2019 Jan; 126(1):113-124. PubMed ID: 30514630
[TBL] [Abstract][Full Text] [Related]
14. Atropine in ameliorating the progression of myopia in children with mild to moderate myopia: a meta-analysis of controlled clinical trials.
Song YY; Wang H; Wang BS; Qi H; Rong ZX; Chen HZ
J Ocul Pharmacol Ther; 2011 Aug; 27(4):361-8. PubMed ID: 21649523
[TBL] [Abstract][Full Text] [Related]
15. A multicenter Spanish study of atropine 0.01% in childhood myopia progression.
Pérez-Flores I; Macías-Murelaga B; Barrio-Barrio J;
Sci Rep; 2021 Nov; 11(1):21748. PubMed ID: 34741059
[TBL] [Abstract][Full Text] [Related]
16. Five-year results of atropine 0.01% efficacy in the myopia control in a European population.
Moriche-Carretero M; Revilla-Amores R; Gutiérrez-Blanco A; Moreno-Morillo FJ; Martinez-Perez C; Sánchez-Tena MÁ; Alvarez-Peregrina C
Br J Ophthalmol; 2024 May; 108(5):715-719. PubMed ID: 37268328
[TBL] [Abstract][Full Text] [Related]
17. Two-Year Clinical Trial of the Low-Concentration Atropine for Myopia Progression (LAMP) Study: Phase 2 Report.
Yam JC; Li FF; Zhang X; Tang SM; Yip BHK; Kam KW; Ko ST; Young AL; Tham CC; Chen LJ; Pang CP
Ophthalmology; 2020 Jul; 127(7):910-919. PubMed ID: 32019700
[TBL] [Abstract][Full Text] [Related]
18. Real-world outcomes of low-dose atropine therapy on myopia progression in an Australian cohort during the COVID-19 pandemic.
Usmani E; Callisto S; Chan WO; Taranath D
Clin Exp Ophthalmol; 2023 Nov; 51(8):775-780. PubMed ID: 37648227
[TBL] [Abstract][Full Text] [Related]
19. Myopia progression following 0.01% atropine cessation in Australian children: Findings from the Western Australia - Atropine for the Treatment of Myopia (WA-ATOM) study.
Lee SS; Nilagiri VK; Lingham G; Blaszkowska M; Sanfilippo PG; Franchina M; Clark A; Mackey DA
Clin Exp Ophthalmol; 2024 Jul; 52(5):507-515. PubMed ID: 38400607
[TBL] [Abstract][Full Text] [Related]
20. Optic Disc Parameters of Myopic Children with Atropine Treatment.
Chan LW; Hsieh YT; Hsu WC; Cheng HC; Shen EP
Curr Eye Res; 2017 Dec; 42(12):1614-1619. PubMed ID: 28937823
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
